Prevention of Seasonal Affective Disorder - Full Text View

Sponsor:	GlaxoSmithKline
Information provided by:	GlaxoSmithKline
ClinicalTrials.gov Identifier:	NCT00046449

Purpose

A Placebo Controlled Study Evaluating The Effectivess Of Medication In Preventing Seasonal Affective Disorder

Condition	Intervention	Phase
Seasonal Affective Disorder (SAD)	Drug: Investigational Seasonal Affective Disorder (SAD) Drug	Phase III

Study Type:	Interventional
Study Design:	Treatment, Randomized, Double-Blind, Placebo Control, Parallel Assignment, Safety/Efficacy Study

Resource links provided by NLM:

MedlinePlus related topics: Seasonal Affective Disorder

U.S. FDA Resources

Eligibility

Ages Eligible for Study:	18 Years and older
Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	No

Criteria

Inclusion Criteria: (Patient must meet these criteria in order to be eligible for this study.)

Patient has a history of Major Depressive Disorder (MDD) with a seasonal pattern.

Exclusion Criteria: (Patient cannot meet these criteria in order to be eligible for this study.)

Patient has a current or past history of seizure disorder or brain injury.
Patient has a history or current diagnosis of anorexia nervousa or bulimia.
Patient has recurrent summer depression more frequently than winter depression.
Patient has primary diagnosis of panic disorder, Obsessive Compulsive Disorder (OCD), Posttraumatic Stress Disorder (PTSD), acute distress disorder, bipolar II disorder or other psychotic disorders.
Patient has initiated psychotherapy within the last 3 months.

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00046449

Hide Study Locations

Locations

United States, Alaska
Study Site
Homer, Alaska, United States, 99603
United States, Connecticut
Study Site
New Haven, Connecticut, United States, 06504-0605
United States, Delaware
Study Site
Newark, Delaware, United States, 19713
Study Site
Wilmington, Delaware, United States, 19808-1251
United States, District of Columbia
Study Site
Washington, District of Columbia, United States, 20016
Study Site
Washington, District of Columbia, United States, 20037
United States, Idaho
Study Site
Boise, Idaho, United States, 83704
United States, Illinois
Study Site
Libertyville, Illinois, United States, 60048
Study SIte
Northfield, Illinois, United States, 60093
Study SIte
Chicago, Illinois, United States, 60610
Study Site
Hoffman Estates, Illinois, United States, 60194
Study Site
Chicago, Illinois, United States, 60612
Study Site
Schaumburg, Illinois, United States, 60194
United States, Indiana
Study SIte
Greenwood, Indiana, United States, 46143
Study Site
Indianapolis, Indiana, United States, 45202
United States, Kentucky
Study Site
Florence, Kentucky, United States, 41042
United States, Massachusetts
Study Site
Wellesley Hills, Massachusetts, United States, 02481
United States, Michigan
Study Site
Okemos, Michigan, United States, 48864
Study Site
Royal Oak, Michigan, United States, 48067
United States, Minnesota
Study Site
Minneapolis, Minnesota, United States, 55454
United States, New Jersey
Study Site
Piscataway, New Jersey, United States, 08854
Study Site
Moorestown, New Jersey, United States, 08057
United States, New York
Study Site
Williamsville, New York, United States, 14221
Study Site
Lawrence, New York, United States, 11559
Study Site
Staten Island, New York, United States, 10305
Study Site
Olean, New York, United States, 14760
Study Site
New York, New York, United States, 10021
Study Site
New York, New York, United States, 10021
Study Site
Amityville, New York, United States, 11701
United States, Ohio
Study Site
Cleveland, Ohio, United States, 44121
Study Site
Cleveland, Ohio, United States, 44106
Study Site
Cincinnati, Ohio, United States, 45219
Study Site
Lyndhurst, Ohio, United States, 44124
Study Site
Toledo, Ohio, United States, 43623
Study Site
Independence, Ohio, United States, 44131
United States, Oregon
Study Site
Salem, Oregon, United States, 97309
Study Site
Portland, Oregon, United States, 97201
Study Site
Eugene, Oregon, United States, 97401
Study Site
Portland, Oregon, United States, 97209
United States, Pennsylvania
Study Site
Philadelphia, Pennsylvania, United States, 19106
Study Site
Allentown, Pennsylvania, United States, 18104
Study Site
Philadelphia, Pennsylvania, United States, 19107
United States, Rhode Island
Study Site
Lincoln, Rhode Island, United States, 02865-4208
United States, Washington
Study Site
Seattle, Washington, United States, 98104
United States, Wisconsin
Study Site
West Allis, Wisconsin, United States, 53227
Study Site
Middleton, Wisconsin, United States, 53562
Study Site
Madison, Wisconsin, United States, 53719
Study Site
Milwaukee, Wisconsin, United States, 53226
Canada, Alberta
Study Site
Edmonton, Alberta, Canada, T6G 2C8
Canada, British Columbia
Study Site
Vancouver, British Columbia, Canada, V6Z 1Y6
Canada, New Brunswick
Study Site
Miramichi, New Brunswick, Canada, E1V 3G5
Canada, Nova Scotia
Study Site
Sydney, Nova Scotia, Canada, B1S 2E8
Canada, Ontario
Study Site
Markham, Ontario, Canada, L6B 1A1
Study Site
Mississauga, Ontario, Canada, L4W 1N2
Canada, Quebec
Study Site
Hull, Quebec, Canada, J9A 1K7

Sponsors and Collaborators

GlaxoSmithKline

More Information

No publications provided

Study ID Numbers:	398149
Study First Received:	September 30, 2002
Last Updated:	June 23, 2005
ClinicalTrials.gov Identifier:	NCT00046449 History of Changes
Health Authority:	United States: Food and Drug Administration

Additional relevant MeSH terms:

Seasonal Affective Disorder
Pathologic Processes
Disease

Mental Disorders
Mood Disorders
Depressive Disorder

ClinicalTrials.gov processed this record on November 25, 2009